GeneDx Holdings Corp (NAS:WGS)

$ 96.57 -0.47 (-0.48%) Market Cap: 2.65 Bil Enterprise Value: 2.65 Bil PE Ratio: 0 PB Ratio: 12.96 GF Score: 43/100

Q3 2024 GeneDx Holdings Corp Earnings Call Transcript
Oct 29, 2024

$84.02 (+49.88%)

Earnings
Q2 2024 GeneDx Holdings Corp Earnings Call Transcript
Jul 30, 2024

$30.13 (-10.57%)

Earnings
Q1 2024 GeneDx Holdings Corp Earnings Call Transcript
Apr 29, 2024

$11 (-0.72%)

Earnings
Q4 2023 GeneDx Holdings Corp Earnings Call Transcript
Feb 20, 2024

$5.24 (+3.76%)

Earnings
Q3 2023 GeneDx Holdings Corp Earnings Call Transcript
Oct 30, 2023

$2.67 (-8.56%)

Earnings
Q2 2023 GeneDx Holdings Corp Earnings Call Transcript
Aug 08, 2023

$6.65 (-0.60%)

Earnings
GeneDx Holdings Corp at Goldman Sachs Healthcare Conference Transcript
Jun 12, 2023
Q1 2023 GeneDx Holdings Corp Earnings Call Transcript
May 09, 2023

$8.35 (-5.65%)

Earnings
Q4 2022 GeneDx Holdings Corp Earnings Call Transcript
Mar 14, 2023

$11.54 (-3.93%)

Earnings
Sema4 Holdings Corp at JPMorgan Healthcare Conference Transcript
Jan 12, 2023
Q3 2022 Sema4 Holdings Corp Earnings Call Transcript
Nov 14, 2022

$29.58 (-12.13%)

Earnings
Q2 2022 Sema4 Holdings Corp Earnings Call Transcript
Aug 15, 2022

$79.2 (-1.23%)

Earnings
Sema4 Holdings Corp at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022
Q1 2022 Sema4 Holdings Corp Earnings Call Transcript
May 12, 2022

$56.76 (+10.26%)

Earnings
Sema4 Holdings Corp Extraordinary Shareholders Meeting Transcript
Apr 27, 2022
Q4 2021 Sema4 Holdings Corp Earnings Call Transcript
Mar 14, 2022

$87.45 (-6.69%)

Earnings
Sema4 Holdings Corp To Acquire GeneDx Inc Call Transcript
Jan 18, 2022
Sema4 Holdings Corp at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 10, 2022
Q3 2021 Sema4 Holdings Corp Earnings Call Transcript
Nov 15, 2021

$258.06 (-2.49%)

Earnings
Sema4 Holdings Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 13, 2021
Q2 2021 Sema4 Holdings Corp Earnings Call Transcript
Aug 16, 2021

Earnings

Sema4 Holdings Corp To Acquire GeneDx Inc Call Transcript

Jan 18, 2022 / 01:00PM GMT

Release Date Price: $113.85 (-14.60%)

Transcript

Operator

Good day, and thank you for standing by. Welcome to the Sema4 to Acquire GeneDx Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Joel Kaufman, Vice President of Finance and Corporate Development. Please go ahead.

Joel Harrison Kaufman

Sema4 Holdings Corp. - VP of Finance & Corporate Development

Thank you. Good morning everyone. Thank you all for participating in today's conference call. Participating for the company today will be Eric Schadt, Founder and Chief Executive Officer of Sema4; Katherine Stueland, Chief Executive Officer of GeneDx; and Isaac Ro, Chief Financial Officer at Sema4.

Earlier today, Sema4 announced that it has entered into a definitive agreement to acquire GeneDx. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.